New approaches for pancreatic cancer in Japan

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue SUPPL. 1, 2004, Pages

  Okusaka, Takuji ^a   Matsumura, Yasuhiro ^b   Aoki, Kazunori ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Chemotherapy; Gemcitabine; Gene therapy; Pancreatic cancer

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; COMPLEMENTARY RNA; DOXORUBICIN; EXATECAN; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MACROGOL; METHOTREXATE; MITOMYCIN C; NK 911; OXONATE POTASSIUM; POLYASPARTIC ACID; RECOMBINANT ALPHA INTERFERON; TEGAFUR; UFT; UNCLASSIFIED DRUG; URACIL;

ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BILIARY TRACT CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TARGETING; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; HUMAN; JAPAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOPENIA; LONG TERM CARE; METASTASIS; MOLECULAR BIOLOGY; NAUSEA; NONHUMAN; PANCREAS CANCER; PATIENT SATISFACTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; FLUOROURACIL; GENE THERAPY; HUMANS; INFUSIONS, INTRA-ARTERIAL; JAPAN; PANCREATIC NEOPLASMS; STEM CELL TRANSPLANTATION;

EID: 8744264813     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0891-1     Document Type: Conference Paper

References (33)

1. Aoki K, Yoshida T, Sugimura T, Terada M (1995) Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 55:3810
2. Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M (1997) Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol Carcinog 20:251
3. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403
4. Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J (1999) Successful treatment of metastatic renal cell carcinoma with nonmyeloablative allogeneic peripheral-blood progenitor-cell transplantation: evidence for a graft-versus-tumor effect. J Clin Oncol 17:2044
5. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ, Clave E, Epperson D, Mayo V (2000) Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750
6. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, Bock G, Gassner C, Schiller L, Petersen F, Niederwieser D (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501
7. Furuse K, Kawahara M, Hasegawa K, Kudoh S, Takada M, Sugiura T, Ichinose Y, Fukuoka M, Ohashi Y, Niitani H (2001) Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol 6:236
8. Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, Oku T, Akiyama T, Kusakabe T, Miyanishi K, Niitsu Y (2000) A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer 89:303
9. Ikeda M, Okada S, Ueno H, Okusaka T, Tanaka N, Kuriyama H, Yoshimori M (2000) A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer. Hepatogastroenterology 47:862
10. Kataoka K, Kwon GS, Yokoyama M, Okano T, Sakurai Y (1993) Block copolymer micelles as vehicles for drug delivery. J Control Release 24:119
11. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K, Niitani H (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85:939
12. Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58:191
13. Matsumura Y (2003) Phase I clinical trial of NK911, polymer micelle encapsulated doxorubicin. Proceedings of the Winter Symposium and 11th International Symposium on Recent Advances in Drug Delivery Systems; Salt-lake City, UT, 3-6 March 2003. Abstract 55
14. Miura Y, Suzuki K, Hatanaka K, Yoshida K, Ohnami S, Kitade Y, Yoshida T, Aoki K (2003) Synergistic cytotoxic effect of antisense K-ras RNA and interferon alpha against pancreatic cancer cells. Mol Ther [Suppl] 7:S417
15. Nose H, Okada S, Okusaka T, Furuse J, Yoshino M, Ogoshi K, Kato T, Miyaji M, Hoshino M, Ariyama J, Suyama M, Karasawa E, Yoshimori M (1999) 5-Fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: a Japanese Cooperative Study. Hepatogastroenterology 46:3244
16. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T, for the S-1 Cooperative Colorectal Carcinoma Study Group (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83:141
17. Okada S (1999) Non surgical treatments of pancreatic cancer. Int J Clin Oncol 4:257
18. Okada S, Ueno H, Okusaka T, Ikeda M, Furuse J, Maru Y (2001) Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 31:7
19. Okada S, Okusaka T, Ueno H, Ikeda M, Kuriyama H, Saisho T, Morizane C (2002) A phase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer (abstract 682). Proc Am Soc Clin Oncol 21
20. Okusaka T, Okada S, Ishii H, Nose H, Nakasuka H, Nakayama H, Nagahama H (1996) Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer. Jpn J Clin Oncol 26:215
21. Omuro Y, Matsumoto G, Sasaki T, Tanaka Y, Maeda Y, Sakamaki H, Hiruma K, Tsuruta K, Takahashi T (2003) Regression of an unresectable pancreatic tumor following nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. Bone Marrow Transplant 31:943
22. Ota K, Taguchi T, Kimura K (1988) Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22:333
23. Rocha Lima CMS, Rotche R, Jeffery M, Trudeau M, Cisar LA, Morganti A, Gruia G, Miller L, Green MR (2003) A randomized phase 3 study comparing efficacy and safety of gemcitabine and irinotecan to GEM alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy (abstract 1005). Proc Am Soc Clin Oncol 22:251
24. Sakata Y, Shimada Y, Yoshino M, Kambe M, Futatsuki K, Nakao I, Ogawa N, Wakui A, Taguchi T (1994) A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer (in Japanese). Gan To Kagaku Ryoho 21:1039
25. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715
26. Statistics and Information Department, Minister's Secretariat (2002) Vital statistics of Japan 2001 (in Japanese). Ministry of Health, Labor and Welfare, Tokyo
27. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T (1999) An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology 57:202
28. Taguchi T, Furuse K, Fukuoka M, Shimoyama T, Morimoto K, Nakamura T, Furue H, Majima H, Niitani H, Ohta K, Wakui A, Nakao I, Tsukagoshi S (1996) LY188011 phase I study. Research Group of Gemcitabine (LY188011) (in Japanese). Gan To Kagaku Ryoho 23:1011
29. Takada T, Nimura Y, Katoh H, Nagakawa T, Nakayama T, Matsushiro T, Amano H, Wada K (1998) Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology 45:2020
30. Tsuji A, Morita S, Horimi T, Takamats M, Takahashi I, Shirasaka T (2002) A phase II study of 5-FU (CVI) and low-dose consecutive CDDP (LFP) therapy in advanced pancreatic cancer (abstract 628). Proc Am Soc Clin Oncol 21
31. Ueno H, Okada S, Okusaka T, Ikeda M, Kuriyama H (2002) Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. Oncology 62:223
32. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE (1998) Allogeneic peripheral-blood progenitor cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16:986
33. Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu-Boue A, Verweij J (1995) Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC Early Clinical Trials Group study. Ann Oncol 6:129